Buscar

01/06/2025 Adverse drug events associated with emergency departments visits
Ramos, JR, Perrín, RS, Martín, MAG, Clemente, YC, Díez, MA, Pinto, AD, Díaz, AS, Almela, AFD, Serrano, PS, Grande, ASL, Blanco, CC. Adverse drug events associated with emergency departments visits. EMERGENCIAS. 2025; 37(3)DOI:10.55633/s3me/025.2025. PMID:. IF:6.300(Q1/1D).
16/02/2024 National expert consensus on home-administered oncologic therapies in Spain
Villegas, E, Arruñada, M, Casado, MA, González, S, Moreno-Martínez, ME, Peñuelas, MA, Torres, AM, Sierra, Y, Seguí, MA. National expert consensus on home-administered oncologic therapies in Spain. Frontiers in Oncology. 2024; 14DOI:10.3389/fonc.2024.1335344. PMID:38434688. IF:3.300(Q2/4D).
01/03/2024 Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study
Torres, T, Chiricozzi, A, Puig, L, Lé, AM, Marzano, AV, Dapavo, P, Dauden, E, Carrascosa, JM, Lazaridou, E, Duarte, G, Carvalho, AVE, Romiti, R, Rompoti, N, Teixeira, L, Abreu, M, Ippoliti, E, Maronese, CA, Llamas-Velasco, M, Vilarrasa, E, del Alcázar, E, Daponte, AI, Papoutsaki, M, Carugno, A, Bellinato, F, Gisondi, P. Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2024; 25(2)DOI:10.1007/s40257-024-00845-4. PMID:38265746. IF:8.800(Q1/1D).
01/12/2025 Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicentre retrospective study
Torres, T, Sood, S, Yilmaz, O, Vender, RB, Prajapati, V, Puig, L, Megna, M, Marzano, AV, Gisondi, P, Carrascosa, JM, Dauden, E, Llamas-Velasco, M, Balato, A, Leal, BG, Prignano, F, Bellinato, F, Silvi, G, Di Brizzi, E, Potestio, L, Sechi, A, Carrera, CG, López-Ferrer, A, Del-Alcazar, E, Mufti, A, Maul, LV, Piaserico, S, Maul, JT, Yeung, J. Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicentre retrospective study. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2025; 50(12)DOI:10.1093/ced/llaf342. PMID:40726424. IF:2.800(Q2/4D).
28/10/2024 International Alliance of Urolithiasis (IAU) consensus on miniaturized percutaneous nephrolithotomy
Zeng, GH, Zhong, W, Mazzon, G, Zhu, W, Lahme, S, Khadgi, S, Desai, J, Agrawal, M, Schulsinger, D, Gupta, M, Montanari, E, Martinez, JML, Almousawi, S, Malonzo, VEF, Sriprasad, S, Arumuham, V, Ferretti, S, Kamal, W, Xu, KW, Cheng, F, Gao, XF, Cheng, JW, Somani, B, Duvdevani, M, Git, KA, Seitz, C, Bernardo, N, Ibrahim, TAA, Aquino, A, Yasui, T, Fiori, C, Knoll, T, Papatsoris, A, Gadzhiev, N, Zhanbyrbekuly, U, Angerri, O, Ramos, HL, Saltirov, I, Moussa, M, Giusti, G, Vicentini, F, Suarez, EB, Pearle, M, Preminger, GM, Wu, QH, Durutovic, O, Ghani, K, Maroccolo, M, Brehmer, M, Osther, PJ, Zawadzki, M, Tursunkulov, A, Kytaibekovich, MN, Abuvohidov, AA, Lara, CAR, Noori, Z, Zanetti, SP, Shrestha, S, de la Rosette, J, Denstedt, J, Ye, ZQ, Sarica, K, Choong, S. International Alliance of Urolithiasis (IAU) consensus on miniaturized percutaneous nephrolithotomy. Military Medical Research. 2024; 11(1)DOI:10.1186/s40779-024-00562-3. PMID:39465407. IF:22.900(Q1/1D).
01/07/2024 Repeat Transurethral Resection (TUR) plus Bacillus Calmette-Guérin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study
Soria, F, Rosazza, M, Livoti, S, Dutto, D, Colucci, F, Sylvester, RJ, Shariat, SF, Babjuk, M, Palou, J, Gontero, P. Repeat Transurethral Resection (TUR) plus Bacillus Calmette-Guérin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study. European Urology Focus. 2024; 10(4)DOI:10.1016/j.euf.2023.10.019. PMID:37923633. IF:5.600(Q1/1D).